IP Library Granted Patent US 8,785,423
Granted Patent B2
US 8,785,423 · App. 12/937,900 · Granted Jul 22, 2014

Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases

Inventors: Vincent Njar (Landsdale, PA); Angela Brodie (Fulton, MD); Robert Bruno (Columbia, MD)
Assignee: University of Maryland, Baltimore
A61K31/58A61K45/06A61K33/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,785,423
App. No.
12/937,900
Granted
Jul 22, 2014
Kind
B2
Abstract

The present invention provides methods of inducing cell cycle arrest and/or cell growth inhibition, with the methods comprising administering to the cells an effective dose of the compounds of the present invention.

Claims (9)

1. A method of causing an effect in a prostate cancer cell, wherein the effect is selected from the group consisting of inducing cell cycle arrest in a cell, inducing growth arrest in a cell and inducing apoptosis in a cell, the method comprising coadministering, sequentially or coextensively, to the prostate cancer cell of a patient in need thereof an effective dose of a combination of an amount of a compound of Formula II and

and an amount of thapsigargin, wherein coadministration of the amount of the compound and the amount of thapsigargin to the cell causes said effect in the cell.

2. The method of claim 1 , wherein the cell is a human cell.

3. The method of claim 1 , wherein the effect is inducing apoptosis.

4. The method of claim 1 , wherein the effect is inducing cell cycle arrest.

5. The method of claim 1 , wherein the effect is cell growth arrest.

6. The method of claim 1 , wherein the amount of thapsigargin is 10 nM thapsigargin.

7. The method of claim 1 , wherein the amount of the compound of Formula II is between about 5 μM to 10 μM.

8. The method of claim 1 , wherein the coadministering further comprises administering an amount of an additional agent that induces ER stress, wherein the additional agent that induces ER stress is selected from the group consisting of cisplatin, gentamicin, bortezomib, eeyarestatin, sorafenib, and docosahexaenoic acid (DHA).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2012
From: NJAR, VINCENT C.O.; BRODIE, ANGELA M.H.; BRUNO, ROBERT D.
To: UNIVERSITY OF MARYLAND, BALTIMORE
Reel/Frame 028450/0769 →
CONFIRMATORY LICENSE Recorded Nov 18, 2010
From: THE UNIVERSITY OF MARYLAND, BALTIMORE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025387/0312 →
Continuity (2)
Provisional Application 61044621 · Apr 14, 2008
Related Publication 20110160170A1 · Jun 30, 2011